Sign In
Buy BIIB
$196.45
+0.490 (+0.250%)
At Close: Jun 04, 2026
Biogen Inc. (BIIB) Sees a More Significant Dip Than Broader Market: Some Facts to Know
07:33pm, Wednesday, 03'rd Jan 2024
In the latest trading session, Biogen Inc. (BIIB) closed at $263.43, marking a -1.6% move from the previous day.
Biogen Inc. (BIIB) Stock Declines While Market Improves: Some Information for Investors
07:35pm, Thursday, 28'th Dec 2023
The latest trading day saw Biogen Inc. (BIIB) settling at $260.58, representing a -0.52% change from its previous close.
Healthcare Heroes: 3 Stocks Innovating in Medicine and Wellness
05:31pm, Wednesday, 27'th Dec 2023
The United States leads globally in the healthcare sector, with its innovative healthcare stocks drawing attention from an impressive $4.3 trillion in spending. As the American Medical Association hig
Top 3 Healthcare Stock Picks for the New Year
08:14pm, Monday, 25'th Dec 2023
After lagging most sectors in 2023, healthcare stocks could deliver substantial returns in 2024. The market has been overly pessimistic about the sector due to short-term challenges.
Election noise may make pharmaceutical stocks 'untenable' for investors, says Mizuho's Jared Holz
02:50pm, Wednesday, 20'th Dec 2023
Jared Holz, Mizuho healthcare sector specialist, joins 'The Exchange' to discuss the 2024 outlook for health care, which stocks to buy in the new year, and more.
Biogen ‘welcomes' EC decision to revoke CMAs for generic versions of Tecfidera
07:49am, Tuesday, 19'th Dec 2023
Biogen Inc. BIIB, +0.89% said Tuesday that the European Commission has revoked the centralized marketing authorizations for generic versions of the biotechnology company's multiple sclerosis treatment
Wells Fargo's top pharma picks for 2024
05:33pm, Friday, 15'th Dec 2023
Mohit Bansal, Wells Fargo Analyst, joins 'Closing Bell: Overtime' to discuss Wells Fargo's pharma picks for 2024.
Mind-Bending Growth: 3 Psychedelic Stocks With Trippy Potential
07:43pm, Thursday, 14'th Dec 2023
Mental health has been one of the hot topics in the medical industry over the past few years. Widespread awareness was brought to the public eye during the COVID-19 pandemic as people in prolonged loc
Alzheimer's Disease Space Evolves in 2023: Stocks in Focus
10:32am, Monday, 11'th Dec 2023
The approval of the breakthrough treatment Leqembi for Alzheimer's Disease has put this space in the spotlight. Companies like ACIU, VAXX and PRTA are in focus, given their experimental vaccines.
2 Popular Stocks to Avoid Like the Plague in 2024 and Beyond
01:52pm, Saturday, 09'th Dec 2023
Aurora Cannabis' latest financial results were decent, but that doesn't make up for years of poor performance. Biogen has proven it can be a highly innovative biotech, but it will take more than that
Why Is Biogen Inc. (BIIB) Up 6.4% Since Last Earnings Report?
12:48pm, Friday, 08'th Dec 2023
Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock?
Alzheimer's Disease Drug Development: Another Lost Year
03:58am, Tuesday, 05'th Dec 2023
Investing in most current Alzheimer's drug companies is not recommended because they are not likely to modify the disease. Compounds that inhibit oxidative stress may only slow down the progression of
Biogen: LAQEMBI's $10 Billion Potential
03:00pm, Wednesday, 29'th Nov 2023
Biogen's latest Alzheimer's drug, Aduhelm, faced challenges after FDA approval, leading to concerns about efficacy and high costs. Biogen and Eisai's latest FDA-approved lecanemab faces similar risks;
Biogen Inc. (BIIB) Evercore ISI 6th Annual HealthCONx Conference (Transcript)
12:12pm, Tuesday, 28'th Nov 2023
Biogen Inc. (NASDAQ:BIIB ) Evercore ISI 6th Annual HealthCONx Conference November 28, 2023 9:10 AM ET Company Participants Priya Singhal - Head of Development Conference Call Participants Umer Raffat
The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks?
06:50am, Friday, 10'th Nov 2023
There's now more than one medicine on the market to treat Alzheimer's disease. Safety and efficacy will be the two major areas of future competition.
